$BIAFJun 18, 2026, 6:55 PMAI processed
bioAffinity (BIAF/BIAFW) priced 4.0M-share registered offering at $0.80 for $3.2M (closing ~Jun 18)
AI Summary
BioAffinity Technologies priced a registered public offering of 4,000,000 shares of common stock (or pre-funded warrants in lieu) at $0.80 per share (or $0.793 per pre-funded warrant) for aggregate gross proceeds of $3.2 million. Pre-funded warrants are immediately exercisable; WallachBeth Capital acted as sole placement agent. The press release says the closing is expected to occur on or about June 18, 2026, so dilution is tied to that closing date. Timing: Warrant exercises are already completed, so dilution is already in effect.
Positives
- Gross proceeds of $3.2 million before fees and expenses
- Pre-funded warrants priced and exercisable immediately (clarifies exercise terms)
Negatives
- 4,000,000 new shares (or pre-funded warrants) are being issued, increasing share count
- Proceeds are relatively small — limited dilution-offsetting capital
- Pre-funded warrants are immediately exercisable, enabling potential near-term share issuance
Filing Context
Filing and Dilution Context
Earliest dilution
Earliest dilution: already triggered
Dilution status
live_now
Dilution timing
Dilution status: Immediate
Trigger type
already_triggered